Navigation Links
Study Reveals Better Results in Patients Suffering From Depression.

Patients suffer from various psychiatric disease and they throng the hospitals for treatment. Statistics show that a third of these people // suffer from mental depressions of different levels.

Drugs that are used to treat them had a lot of controversial opinion about them and hence a study was conducted to analyze the effect of these drugs on the patients.

The initial results were that the drugs showed better results in case of well-qualified white women. The patients seem to undergo better recovery in their first trail of antidepressants. Dr. Madhukar Trivedi at the University of Texas Southwestern Medical Center carried out this study, which was funded by the National Institute of Mental Health ($35 million).

But in the earlier times treating patients with depression was a very challenging task. The first set of antidepressants will not usually work with the patients and the doctors would have to mix and match various drugs in order to find the exact cure for the particular patient.

The study (STAR-D) involved monitoring of the doctors especially in the initial months of the antidepressant’s usage.

The main idea to go about with this study is that there were evidences proving that antidepressants on certain periods led to increased suicidal tendencies in children/teenagers.

The Food and Drug Administration (FDA) has ordered that the pharmaceutical companies include the risks of children on the product labels. The study also said that in the future they would analyze the adult risk of usage of these antidepressants.

The results of the study were that it did not show any suicidal tendencies among the subjects (3000) included in the study.

The STAR-D study, which is a six-year study, was analyzed in two steps.

In step one the patients were given a newer class of antidepressants of selective serotonin reuptakes (Celexa). It showed that white women who were well qualified and patients who suffered from less number of diseases recovered quickly with initial treatment than who had severe depression and a number of co-existing diseases.

Patients who were not cured moved to the second step where they were administered with different therapies for difficult to treat depressions.

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... amputations in the United States. Podiatrists are well aware that psychology-based patient non-compliance ... behaviors) are often catastrophic contributors to diseases of the diabetic foot. The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile imaging results ... subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating new ... America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at Booth ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology: